Latest news with #MyriadGenetics
Yahoo
30-05-2025
- Business
- Yahoo
3 Cash-Burning Stocks Facing Headwinds
Rapid spending isn't always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable. Negative cash flow can lead to trouble, but StockStory helps you identify the businesses that stand a chance of making it through. That said, here are three cash-burning companies to avoid and some better opportunities instead. Trailing 12-Month Free Cash Flow Margin: -2.1% Cooling America's first indoor ice rink in the 19th century, Enviri (NYSE:NVRI) offers steel and waste handling services. Why Should You Sell NVRI? Sales trends were unexciting over the last two years as its 7.1% annual growth was below the typical industrials company Cash-burning history makes us doubt the long-term viability of its business model Limited cash reserves may force the company to seek unfavorable financing terms that could dilute shareholders Enviri's stock price of $8.15 implies a valuation ratio of 2.6x forward EV-to-EBITDA. If you're considering NVRI for your portfolio, see our FREE research report to learn more. Trailing 12-Month Free Cash Flow Margin: -2.9% Founded in 1991 as one of the pioneers in translating genetic discoveries into clinical applications, Myriad Genetics (NASDAQ:MYGN) develops genetic tests that assess disease risk, guide treatment decisions, and provide insights across oncology, women's health, and mental health. Why Do We Think MYGN Will Underperform? Annual revenue growth of 1.8% over the last five years was below our standards for the healthcare sector Earnings per share fell by 29.7% annually over the last five years while its revenue grew, showing its incremental sales were much less profitable Negative returns on capital show that some of its growth strategies have backfired, and its shrinking returns suggest its past profit sources are losing steam Myriad Genetics is trading at $4.09 per share, or 32.5x forward P/E. To fully understand why you should be careful with MYGN, check out our full research report (it's free). Trailing 12-Month Free Cash Flow Margin: -1.8% Following its 2023 acquisition of DISH Network, EchoStar (NASDAQ:SATS) provides satellite communications, pay-TV services, wireless networks, and broadband solutions across consumer and enterprise markets. Why Are We Cautious About SATS? Incremental sales over the last five years were much less profitable as its earnings per share fell by 11.5% annually while its revenue grew 6.8 percentage point decline in its free cash flow margin over the last five years reflects the company's increased investments to defend its market position Unfavorable liquidity position could lead to additional equity financing that dilutes shareholders At $20.50 per share, EchoStar trades at 3.6x forward EV-to-EBITDA. Read our free research report to see why you should think twice about including SATS in your portfolio, it's free. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio
Yahoo
28-05-2025
- Health
- Yahoo
Myriad Genetics, Inc. (MYGN) Showcases Breakthrough MRD Data and AI-Driven Cancer Tools at ASCO 2025
Myriad Genetics, Inc. (NASDAQ:MYGN) is making waves at the 2025 ASCO Annual Meeting, presenting seven new research studies that underscore major advances in molecular diagnostics and precision oncology. Among the highlights is the MONSTAR-SCREEN-3 study, which demonstrates the power of Myriad Genetics, Inc. (NASDAQ:MYGN)'s whole-genome sequencing-based Precise MRD test to detect circulating tumor DNA (ctDNA) with unprecedented sensitivity across multiple cancer types, achieving 100% baseline detection and identifying tumor fractions as low as 0.0001%. This technology also flags cancer recurrence earlier than traditional imaging. A biotechnologist in a laboratory testing an Immuno-oncology treatment. Other studies include ultrasensitive ctDNA monitoring in metastatic breast cancer, ancestry-specific cancer risk variants, and expanded genetic testing for hereditary cancers. Myriad Genetics, Inc. (NASDAQ:MYGN) also announced upcoming launches: a commercial Precise MRD test in 2026, an AI-powered Prolaris prostate cancer test with PATHOMIQ, and an expanded MyRisk hereditary cancer panel. Full integration with leading EMR platforms like Flatiron's OncoEMR and Epic is planned for later this year, further streamlining clinical workflows. While we acknowledge the potential of MYGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MYGN and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data
Yahoo
27-05-2025
- Business
- Yahoo
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let's have a look at Myriad Genetics (NASDAQ:MYGN) and its peers. Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases and disorders, face strong tailwinds from advancements in precision medicine (including the use of AI to improve hit rates) and growing demand for treatments targeting rare diseases. However, headwinds such as rising scrutiny over drug pricing, regulatory unknowns, and competition from larger, more resourced pharmaceutical companies could weigh on growth. The 10 therapeutics stocks we track reported a mixed Q1. As a group, revenues beat analysts' consensus estimates by 1.2%. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 9% since the latest earnings results. Founded in 1991 as one of the pioneers in translating genetic discoveries into clinical applications, Myriad Genetics (NASDAQ:MYGN) develops genetic tests that assess disease risk, guide treatment decisions, and provide insights across oncology, women's health, and mental health. Myriad Genetics reported revenues of $195.9 million, down 3.1% year on year. This print fell short of analysts' expectations by 2.3%. Overall, it was a softer quarter for the company with full-year revenue guidance missing analysts' expectations. 'We had a challenging first quarter of 2025 with strength in our prenatal and oncology MyRisk tests offset by softness in GeneSight and unaffected hereditary cancer tests. While we are actively working on initiatives to re-accelerate testing volumes, this will take time; therefore we are lowering our 2025 financial guidance. We are taking immediate steps to reduce overall expenditures while prioritizing investment in new product development and programs intended to drive revenue growth,' said Sam Raha, President and CEO, of Myriad Genetics. Unsurprisingly, the stock is down 45% since reporting and currently trades at $3.99. Read our full report on Myriad Genetics here, it's free. Founded by a mother seeking treatment for her daughter's pulmonary arterial hypertension, United Therapeutics (NASDAQ:UTHR) develops and commercializes medications for chronic lung diseases and other life-threatening conditions, with a focus on pulmonary hypertension treatments. United Therapeutics reported revenues of $794.4 million, up 17.2% year on year, outperforming analysts' expectations by 5.6%. The business had a very strong quarter with a narrow beat of analysts' EPS estimates. However, the results were likely priced into the stock as it's traded sideways since reporting. Shares currently sit at $302.50. Is now the time to buy United Therapeutics? Access our full analysis of the earnings results here, it's free. Founded in 1989 with a mission to create medicines that treat the underlying causes of disease rather than just symptoms, Vertex Pharmaceuticals (NASDAQ:VRTX) develops and markets transformative medicines for serious diseases, with a focus on cystic fibrosis, sickle cell disease, and pain management. Vertex Pharmaceuticals reported revenues of $2.77 billion, up 3% year on year, falling short of analysts' expectations by 2.3%. It was a disappointing quarter as it posted a significant miss of analysts' EPS estimates. As expected, the stock is down 13.1% since the results and currently trades at $434.31. Read our full analysis of Vertex Pharmaceuticals's results here. Born from a 2013 spinoff of Abbott Laboratories' pharmaceutical business, AbbVie (NYSE:ABBV) is a biopharmaceutical company that develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions. AbbVie reported revenues of $13.34 billion, up 8.4% year on year. This number beat analysts' expectations by 3.3%. Overall, it was a very strong quarter as it also logged a solid beat of analysts' constant currency revenue estimates and a decent beat of analysts' EPS estimates. The stock is up 1.5% since reporting and currently trades at $183.25. Read our full, actionable report on AbbVie here, it's free. Pioneering treatments for conditions that often had no previous therapeutic options, BioMarin Pharmaceutical (NASDAQ:BMRN) develops and commercializes therapies that address the root causes of rare genetic disorders, particularly those affecting children. BioMarin Pharmaceutical reported revenues of $745.1 million, up 14.8% year on year. This result topped analysts' expectations by 1%. It was a strong quarter as it also put up a solid beat of analysts' EPS estimates and full-year revenue guidance meeting analysts' expectations. BioMarin Pharmaceutical delivered the highest full-year guidance raise among its peers. The stock is down 8.3% since reporting and currently trades at $57.56. Read our full, actionable report on BioMarin Pharmaceutical here, it's free. Thanks to the Fed's rate hikes in 2022 and 2023, inflation has been on a steady path downward, easing back toward that 2% sweet spot. Fortunately (miraculously to some), all this tightening didn't send the economy tumbling into a recession, so here we are, cautiously celebrating a soft landing. The cherry on top? Recent rate cuts (half a point in September 2024, a quarter in November) have propped up markets, especially after Trump's November win lit a fire under major indices and sent them to all-time highs. However, there's still plenty to ponder — tariffs, corporate tax cuts, and what 2025 might hold for the economy. Want to invest in winners with rock-solid fundamentals? Check out our 9 Best Market-Beating Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here. Sign in to access your portfolio
Business Insider
21-05-2025
- Business
- Business Insider
Myriad Genetics downgraded to Sector Perform from Outperform at Scotiabank
Scotiabank downgraded Myriad Genetics (MYGN) to Sector Perform from Outperform with a $6 price target Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
20-05-2025
- Business
- Yahoo
MYGN Q1 Earnings Call: Guidance Cut Amid GeneSight Challenges and Slow Hereditary Cancer Ramp
Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell short of the market's revenue expectations in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million. The company's full-year revenue guidance of $815 million at the midpoint came in 3.7% below analysts' estimates. Its non-GAAP loss of $0.03 per share was $0.02 above analysts' consensus estimates. Is now the time to buy MYGN? Find out in our full research report (it's free). Revenue: $195.9 million vs analyst estimates of $200.4 million (3.1% year-on-year decline, 2.3% miss) Adjusted EPS: -$0.03 vs analyst estimates of -$0.05 ($0.02 beat) Adjusted EBITDA: -$640,000 vs analyst estimates of -$1.92 million (-0.3% margin, 66.6% beat) The company dropped its revenue guidance for the full year to $815 million at the midpoint from $850 million, a 4.1% decrease Adjusted EPS guidance for Q2 CY2025 is $0 at the midpoint, below analyst estimates of $0.02 EBITDA guidance for the full year is $23 million at the midpoint, below analyst estimates of $29.85 million Operating Margin: -14.8%, down from -13.8% in the same quarter last year Free Cash Flow was -$21.6 million compared to -$25.3 million in the same quarter last year Market Capitalization: $380.7 million Myriad Genetics' first quarter results reflected a combination of headwinds and pockets of growth across its genetic testing portfolio. Management attributed the revenue decline primarily to lower volumes in its GeneSight pharmacogenomics test and softness in hereditary cancer testing for unaffected patients, while also highlighting continued strength in prenatal and oncology-related products. President and CEO Sam Raha described the quarter as challenging, noting, 'Strength in our prenatal and oncology MyRisk tests were offset by softness in volume for GeneSight and unaffected hereditary cancer tests,' and acknowledged the need for improved execution in certain segments. Looking ahead, the company's full-year guidance was revised downward due to expectations for continued softness in GeneSight and hereditary cancer test volumes. Management emphasized a renewed focus on operational efficiency and product launches, especially the upcoming First Gene combined carrier screening and NIPS assay. Raha stated, 'We have started taking deliberate steps to reduce our overall projected spending while prioritizing investments and resources on driving 2025 revenue and high-value new product development.' The leadership team signaled a period of strategic reassessment, with a strategy refresh expected later this year. Myriad Genetics' management detailed the primary factors shaping first quarter performance and provided updates on business segments and upcoming initiatives. GeneSight Coverage Headwinds: The UnitedHealthcare policy change for GeneSight, effective January 1, contributed to a substantial reduction in revenue from this product line. Management explained that reduced marketing spend and commercial resources further impacted GeneSight's volume, and noted that the majority of the $35 million revenue guidance cut was tied to these dynamics. Hereditary Cancer Workflow Challenges: Hereditary cancer testing for unaffected individuals experienced flat volumes due to slower-than-anticipated adoption of electronic medical record (EMR) integrations and lower ramp from breast cancer risk assessment programs. Management cited technical workflow hurdles and outlined plans to address these issues account by account, expecting several quarters to achieve stabilization. Prenatal and Oncology Segment Growth: Prenatal tests (notably ForeSight and Prequel) and MyRisk hereditary cancer tests for affected patients showed double-digit volume growth, offsetting some declines in other areas. The company highlighted the positive impact of recent product launches and deeper account penetration in these segments. Strategic Product Pipeline: Management reaffirmed its commitment to launching the First Gene combined carrier screening and NIPS assay by mid-year, advancing the PRECISE MRD minimal residual disease test (with clinical data presented at recent conferences), and introducing an AI-enabled Prolaris test for prostate cancer by year-end. Leadership and Organizational Changes: Recent executive appointments were emphasized, including Mark Verratti as Chief Operating Officer and Brian Donnelly as Chief Commercial Officer, alongside targeted hiring in oncology R&D and biopharma services. Management described these appointments as foundational to the company's efforts to enhance execution and organizational design. Management's outlook for the remainder of the year centers on addressing operational hurdles in core product lines while prioritizing efficient investment and strategic product launches. The company's guidance reflects expectations for moderate sequential improvement and a continued focus on execution. GeneSight and Hereditary Cancer Recovery: Management plans to implement workflow solutions and targeted commercial strategies to increase GeneSight and hereditary cancer test volumes. However, they acknowledged near-term headwinds and expect a gradual ramp-up as EMR integrations and risk assessment programs scale. Cost Control and Investment Focus: The company intends to reduce discretionary spending, limit headcount growth, and reallocate resources to high-priority projects, including key product launches and EMR integration initiatives. Management expects these steps to drive incremental margin improvement without compromising strategic growth. Product Launch Milestones: Upcoming launches of the First Gene combined carrier screening/NIPS assay and the AI-enabled Prolaris test are expected to be important catalysts for revenue growth, contingent on timely execution and successful market adoption. Doug Schenkel (Wolfe Research): Questioned the complexity of Myriad's narrative and the timeline for simplifying business operations; management suggested clarity will take several months and identified oncology, volume growth, and new product launches as key metrics. Puneet Souda (Leerink Partners): Asked about potential payer risks for GeneSight beyond UnitedHealthcare and provider behavior; management stated no additional payer losses have occurred and provider ordering patterns remain stable. David Westenberg (Piper Sandler): Requested details on the slow ramp in hereditary cancer testing for unaffected patients; management attributed it to technical EMR workflow issues and outlined ongoing account-specific solutions. Matt Sykes (Goldman Sachs): Inquired about the nature of cost savings; management confirmed cuts are focused on discretionary spend and infrastructure, not core product development or commercial teams. Tejas Sawant (Morgan Stanley): Asked about MRD product sensitivity milestones and the timeline for strategy changes; management highlighted upcoming clinical data releases and committed to a phased strategy refresh by late 2025. In the coming quarters, the StockStory team will be monitoring (1) progress on workflow improvements and EMR integrations that could boost hereditary cancer and GeneSight test volumes, (2) execution and market reception of new product launches, particularly First Gene and AI-enabled Prolaris, and (3) the effectiveness of cost control measures in supporting margin stabilization. Updates on clinical data for the PRECISE MRD test and additional payer coverage wins will also be important markers of future performance. Myriad Genetics currently trades at a forward P/E ratio of 32.6×. In the wake of earnings, is it a buy or sell? Find out in our free research report. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
